Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

Ozempic and Wegovy has been prescribed to Yorkshire patients hundreds of times in the past year - and it's not for weightloss ...

Whoopi Goldberg made it clear she had no involvement with the promotion of any kind of products and warned fans against ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

The EGOT winner railed against an ad that's circulating on social media with a manipulated version of her promoting "bad ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

"The View" co-host Whoopi Goldberg addressed a "phony weight loss ad" circulating on Instagram during the show on Wednesday ...

Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.

GPs could be at medico-legal risk if they ignore requests from online pharmacies for patient information for prescribing ...

Weight-loss jabs such as Ozempic are being hailed as a potential breakthrough in the fight against obesity. Demand, fuelled ...

Almost 2% of the U.S. population received prescriptions for the weight-loss and diabetes drugs semaglutide and tirzepatide in ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...